

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2963465

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
BIOTECH SYNERGY, INC.		06/20/2014
RECEIVING PARTY DATA		
Name:	OSE PHARMA INTERNATIONAL SA	
Street Address:	4 RUE DE L'ATHENEE	
Internal Address:	P.O. BOX 330	
City:	GENEVA	
State/Country:	SWITZERLAND	
Postal Code:	1211	
PROPERTY NUMBERS Total: 21		
Property Type	Number	
Application Number:	09583200	
Application Number:	11482832	
Application Number:	11976908	
Application Number:	13662906	
Application Number:	11978730	
PCT Number:	US0031856	
PCT Number:	US0310571	
Application Number:	11978519	
Application Number:	60463724	
PCT Number:	US2004011895	
Application Number:	10553703	
Application Number:	12710836	
Application Number:	13212847	
Application Number:	14081086	
Application Number:	11980732	
Application Number:	09098584	
Application Number:	09189702	
Application Number:	09458297	
Application Number:	11882719	
PCT Number:	US9913789	

PATENT

Property Type	Number
Application Number:	09543608

CORRESPONDENCE DATA

Fax Number: (626)395-0694

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6263957801

Email: rmdomingo@adrianoassociates.com

Correspondent Name: SARAH B, ADRIANO

Address Line 1: 690 EAST GREEN STREET

Address Line 2: SUITE 300

Address Line 4: PASADENA, CALIFORNIA 91101

ATTORNEY DOCKET NUMBER:	30404.GEN
NAME OF SUBMITTER:	SARAH B. ADRIANO
SIGNATURE:	/Sarah B. Adriano/
DATE SIGNED:	07/31/2014

Total Attachments: 10

source=14 jun 20 Assignment of Patent Rights#page1.tif

source=14 jun 20 Assignment of Patent Rights#page2.tif

source=14 jun 20 Assignment of Patent Rights#page3.tif

source=14 jun 20 Assignment of Patent Rights#page4.tif

source=14 jun 20 Assignment of Patent Rights#page5.tif

source=14 jun 20 Assignment of Patent Rights#page6.tif

source=14 jun 20 Assignment of Patent Rights#page7.tif

source=14 jun 20 Assignment of Patent Rights#page8.tif

source=14 jun 20 Assignment of Patent Rights#page9.tif

source=14 jun 20 Assignment of Patent Rights#page10.tif

ASSIGNMENT OF PATENT RIGHTS

Biotech Synergy, Inc., a corporation duly organized under and pursuant to the laws of California, and having its principal place of business at 5916 Via Zurita, La Jolla, CA 92037 (herein referred to as "Assignor") wishes to convey its entire right, title and interest in any Letters Patent(s) ("said patent(s)") and any Patent application(s) ("said application(s)") set forth on Exhibit A hereto, as well as any inventions(s) ("said invention(s)") disclosed in said application(s) and said patent(s).

WHEREAS, OSE Pharma International SA, a corporation duly organized under and pursuant to the laws of Switzerland, and having its principal place of business at 4 rue de l'Athénée, P.O. Box 330, 1211 Geneva 12, Switzerland (herein referred to as "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), the right to recover damages, including provisional or other royalties, for prior infringements of said application(s) and said patent(s), and the entire right, title, and interest in and to any Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s);

NOW THEREFORE, in consideration of the consideration set forth between Assignor and Assignee dated as of the date hereof and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns its entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), its entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), including divisions, continuations, and continuations-in-part of said application(s), the right to recover damages, including provisional or other

royalties, for prior infringements of said application(s) and said patent(s), its entire right, title and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s), its entire right, title and interest in and to any and all reissues and extensions of said patent(s), and all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND the Assignor hereby requests the Commissioner for Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand this 20th day
of June, 2014.

Emile Loria

Emile Loria
President
Biotech Synergy, Inc.

STATE OF California
COUNTY OF San Diego

On 06/30/2014 before me, James Zivkovic,
appeared Emile Loria, ☐ personally
known to me **OR** ☒ proved to me on the basis of
satisfactory evidence to be the person whose name
is subscribed to the within instrument and
acknowledged to me that he executed the same in
his authorized capacity, and that by his signature on
the instrument the person, or the entity upon behalf
of which the person acted, executed the instrument.

WITNESS my hand and official seal

[SEAL]

I certify under PENALTY OF PERJURY under the
laws of the State of California that the
foregoing paragraph is true and correct.

James Zivkovic
Notary Public




EXHIBIT A

#	DOCKET INVENTORS	APPLICATION # OR PATENT # ISSUE DATE OR FILING DATE	TITLE	STATUS
1	30404.10USD1 John D. Fikes Alessandro Sette John Sidney Scott Southwood Esteban Celis Elissa A. Keogh Robert Chesnut	US 09/583,200 Filed May 30, 2000	HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS	Abandoned
2	30404.10USD1 John D. Fikes Alessandro Sette John Sidney Scott Southwood Esteban Celis Elissa A. Keogh Robert Chesnut	US 11/482,632 Filed July 10, 2006	HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS	Abandoned
3	30404.10USD2 John D. Fikes Alessandro Sette John Sidney Scott Southwood Esteban Celis Elissa A. Keogh Robert Chesnut	US 11/976,908 Filed October 29, 2007	HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS	Abandoned
4	30404.10USC1 John D. Fikes Alessandro Sette John Sidney Scott Southwood, Esteban Celis Elissa A. Keogh	US 13/662,906 Filed October 29, 2012	HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINES COMPOSITIONS	Pending

1 06/20/2014 *Rick Lork*

#	DOCKET INVENTORS	APPLICATION # OR PATENT # ISSUE DATE OR FILING DATE	TITLE	STATUS
5	Robert Chesnut 30404.11USD1 Shabnam Tangri Alessandro Sette Glenn Ishioka John D. Fikes	US 11/978,730 Filed October 30, 2007	HETEROCLITIC ANALOGS AND RELATED METHODS	Abandoned
6	30404.11WO01 Shabnam Tangri Alessandro Sette Glenn Ishioka	PCT/US00/31856 Filed November 20, 2000	HETEROCLITIC ANALOGS AND RELATED METHODS	Inactive
7	30404.11CAWO Shabnam Tangri Alessandro Sette Glenn Ishioka	CA 2,385,341 Filed November 20, 2000	HETEROCLITIC ANALOGS AND RELATED METHODS	Abandoned
8	30404.11EPWO Shabnam Tangri Alessandro Sette Glenn Ishioka	EP Patent 1 230 268 Issued October 14, 2009 EP 00979208.6 Filed November 20, 2000	HETEROCLITIC ANALOGS OF CLASS I EPITOPES	Granted
9	30404.11JPWO Shabnam Tangri Alessandro Sette Glenn Ishioka	JP Patent 4776131 Issued September 21, 2011 JP 2001-538941 Filed November 20, 2000	HETEROCLITIC ANALOGS AND RELATED METHODS	Granted
10	30404.11WO11 Glenn Ishioka John Fikes Shabnam Tangri Alessandro Sette	PCT/US03/10571 Filed April 7, 2003	HETEROCLITIC ANALOGS AND RELATED METHODS	Inactive
11	30404.11AU11 Alessandro Sette Shabnam Tangri John Fikes	AU 2003221831 Filed April 7, 2003	HETEROCLITIC ANALOGS AND RELATED METHODS	Abandoned

2 9/6/2014 2:16 PM

#	DOCKET INVENTORS	APPLICATION # OR PATENT # ISSUE DATE OR FILING DATE	TITLE	STATUS
12	Glenn Ishioka 30404.11CAI1 Glenn Ishioka John Fikes Shabnam Tangri Alessandro Sette	CA 2,481,462 Filed April 7, 2003	HETEROCLITIC ANALOGS AND RELATED METHODS	Abandoned
13	30404.11EP11 Glenn Ishioka John Fikes Shabnam Tangri Alessandro Sette	EP 1 495 322 EP 03716231.8 Filed April 7, 2003	HETEROCLITIC ANALOGS AND RELATED METHODS	Abandoned
14	30404.11JP11 Glenn Ishioka John Fikes Shabnam Tangri Alessandro Sette	JP 2005-522212 JP 2003-584081 Filed April 7, 2003	HETEROCLITIC ANALOGS AND RELATED METHODS	
15	30404.12USD1 Howard M. Grey Alessandro Sette John Sidney Scott Southwood Ralph T. Kubo Esteban Celis Robert Chesnut W. Martin Kast	US 11/978,519 Filed October 30, 2007	HLA BINDING MOTIFS AND PEPTIDES AND THEIR USES	Abandoned
16	30404.13USP1 John D. Fikes Glenn Ishioka Alessandro Sette Robert W. Chesnut	US 60/463,724 Filed April 18, 2003	HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITION	Inactive
17	30404.13WO01 John D. Fikes Glenn Ishioka Alessandro Sette	PCT/US2004/011895 Filed April 16, 2004 WO 2004/094454 Published November 4, 2004	HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS	Inactive

06/20/2014 ³ *Zmishko*

#	DOCKET INVENTORS	APPLICATION # OR PATENT # ISSUE DATE OR FILING DATE	TITLE	STATUS
	John D. Fikes Glenn Ishioka Alessandro Sette Robert W. Chesnut	US 12/710,836 Filed February 23, 2010		
25	30404.13USC2 John D. Fikes Glenn Ishioka Alessandro Sette Robert W. Chesnut	US 13/212,847 Filed August 18, 2011	HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS	Abandoned
26	30404.13USC3 John D. Fikes Glenn Ishioka Alessandro Sette Robert W. Chesnut	US 14/081,086 Filed November 15, 2013	HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS	Pending
27	30404.14US01 John D. Fikes Glenn Ishioka Alessandro Sette Robert W. Chesnut	US 11/980,732	HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS	Abandoned
28	30404.15US01 Alessandro Sette John Sidney Scott Southwood	US 09/098,584 Filed June 17, 1998	HLA BINDING PEPTIDES AND THEIR USES	Abandoned
29	30404.15USI5 Alessandro Sette John Sidney Scott Southwood Esteban Celis	US Patent 7,252,829 Issued August 7, 2007 US 09/189,702 Filed November 10, 1998	HLA BINDING PEPTIDES AND THEIR USES	Granted
30	30404.15USC1 Alessandro Sette John Sidney Scott Southwood Esteban Celis	US 09/458,297 Filed December 10, 1999	HLA BINDING PEPTIDES AND THEIR USES	Abandoned
31	30404.15USC2 Alessandro Sette	US 11/882,719 Filed August 3, 2007	HLA BINDING PEPTIDES AND THEIR USES	Pending

5 96/20/2014 *Dr. C. W. R. R.*

#	DOCKET INVENTORS	APPLICATION # OR PATENT # ISSUE DATE OR FILING DATE	TITLE	STATUS
	John Sidney Scott Southwood Esteban Celis			
32	30404.15WO01 Alessandro Sette John Sidney Scott Southwood	PCT/US99/13789 Filed June 17, 1999	HLA BINDING PEPTIDES AND THEIR USES	Inactive
33	30404.15ATWO Alessandro Sette John Sidney Scott Southwood	AT 429247	HLA BINDING PEPTIDES AND THEIR USES	Abandoned
34	30404.15AUWO Alessandro Sette John Sidney Scott Southwood	AU Patent 4577899 AU 19990045778 Filed June 17, 1999	HLA BINDING PEPTIDES AND THEIR USES	Lapsed
35	30404.15CAWO Alessandro Sette John Sidney Scott Southwood	CA 2,330,824 Filed June 17, 1999	HLA BINDING PEPTIDES AND THEIR USES	Abandoned
36	30404.15DEWO	EP patent EP1089757 (formerly EP patent app 99928792.3)	HLA BINDING PEPTIDES AND THEIR USES	
37	30404.15ESWO	EP patent EP1089757 (formerly EP patent app 99928792.3)	HLA BINDING PEPTIDES AND THEIR USES	
38	30404.15FRWO	EP patent EP1089757 (formerly EP patent app 99928792.3)	HLA BINDING PEPTIDES AND THEIR USES	
39	30404.15GBWO	EP patent EP1089757 (formerly EP patent app 99928792.3)	HLA BINDING PEPTIDES AND THEIR USES	
40	30404.15EPWO	EP patent EP1089757 (formerly EP patent app 99928792.3)	HLA BINDING PEPTIDES AND THEIR USES	

6 06/20/2014 *Ricardo*

#	DOCKET INVENTORS	APPLICATION # OR PATENT # ISSUE DATE OR FILING DATE	TITLE	STATUS
41	30404.15EPD1	EP 2036573 EP 08018213.2 Filed October 17, 2008 JP 2002-518346	HLA BINDING PEPTIDES AND THEIR USES	Abandoned
42	30404.15JPWO	 JP 2000-554400 Filed June 17, 1999 JP 2010-090167	HLA BINDING PEPTIDES AND THEIR USES	
43	30404.15JPW1 Alessandro Sette John Sidney Scott Southwood	JP 2010-004446 Filed January 12, 2010	HLA (HUMAN LEUKOCYTE ANTIGEN) BINDING PEPTIDES AND APPLICATIONS OF THE SAME	
44	30404.19US01 John Fikes Alessandro Sette John Sidney Scott Southwood Esteban Celis Elissa Keogh Robert Chesnut	US Patent 6,602,510 Issued August 5, 2003 US 09/543,608 Filed April 5, 2000	HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS	Granted
45	30404.20CAWO Elissa A. Keogh Scott Southwood John D. Fikes Alessandro Sette	CA 2,511,775 Filed December 10, 2003	HLA-A1, -A2, -A3, -A24, -B7, and -B44 TUMOR ASSOCIATED ANTIGEN PEPTIDE AND COMPOSITIONS	Abandoned

06/20/2014 Erik work